Peficitinib联合有限csDMARDs治疗中重度类风湿关节炎的IIb期研究
这项随机双盲IIb期试验纳入289例中重度类风湿关节炎患者,评估每日一次口服Peficitinib 25、50、100、150 mg或安慰剂联合有限csDMARDs治疗12周的疗效与安全性。结果显示ACR20应答率呈剂量依赖性升高,100 mg和150 mg组自第2周起显著优于安慰剂,总体不良事件发生率与安慰剂相近。
要点
- Peficitinib 100 mg和150 mg组第12周ACR20应答率显著高于安慰剂。
- 100 mg和150 mg组自第2周起即达统计学显著ACR20应答。
- 总体不良事件发生率与安慰剂相似,常见上呼吸道感染、恶心和尿路感染。
核心结论
- 在中重度RA患者中,每日一次口服Peficitinib联合有限csDMARDs治疗12周产生剂量依赖性ACR20应答率且耐受性满意。
研究设计与样本
- 随机双盲IIb期试验纳入289例中重度RA患者,每日一次口服Peficitinib 25、50、100、150 mg或安慰剂联合有限csDMARDs治疗12周。
主要发现
- 第12周ACR20应答率在Peficitinib 25、50、100、150 mg和安慰剂组分别为22.0%、36.8%、48.3%(P < 0.05)、56.3%(P < 0.01)和29.4%。
- Peficitinib 100 mg和150 mg组较安慰剂组快速且统计学显著地达到ACR20应答(P < 0.05),至第2周即达统计学显著性。
- 总体不良事件发生率在Peficitinib组与安慰剂组间相似。
- 最常见不良事件为上呼吸道感染(5% [n = 15])、恶心(4% [n = 12])和尿路感染(4% [n = 10])。
- 安慰剂组有1例带状疱疹,Peficitinib 25 mg组有1例严重感染(肢体脓肿);未发生2级或以上中性粒细胞减少或淋巴细胞减少。
关键数值与推荐
- 主要终点为第12周达到ACR20应答的患者百分比。
- 第12周ACR20应答率:Peficitinib 25 mg组22.0%、50 mg组36.8%、100 mg组48.3%(P < 0.05)、150 mg组56.3%(P < 0.01)、安慰剂组29.4%。
临床怎么用
- 对于中重度RA患者,Peficitinib 100 mg或150 mg每日一次联合有限csDMARDs可在12周内快速提高ACR20应答率。
- 治疗期间需关注上呼吸道感染、恶心、尿路感染及带状疱疹、严重感染等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA). METHODS: In this randomized, double-blind, phase IIb trial, patients with RA (n = 289) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg or matching placebo once daily for 12 weeks. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at week 12. RESULTS: ACR20 response rates at week 12 were 22.0%, 36.8%, 48.3% (P < 0.05), 56.3% (P < 0.01), and 29.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively. Patients in the peficitinib 100 mg and 150 mg groups achieved a rapid and statistically significant ACR20 response compared with those in the placebo group (P < 0.05), reaching statistical significance by week 2. Overall, the incidence of adverse events (AEs) was similar between patients receiving peficitinib and those receiving placebo. The most common AEs were upper respiratory tract infection (5% [n = 15]), nausea (4% [n = 12]), and urinary tract infection (4% [n = 10]). There was 1 case of herpes zoster in the placebo group, and 1 serious infection (limb abscess) in the peficitinib 25 mg group. There were no incidences of grade 2 or higher neutropenia or lymphopenia. CONCLUSION: In patients with moderate-to-severe RA, orally administered once-daily peficitinib in combination with limited csDMARDs resulted in a dose-dependent ACR20 response rate over 12 weeks with satisfactory tolerability.
引用
- Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis. Arthritis Rheumatol. 2017. PMID: 28118538. doi:10.1002/art.40054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。